Merck & Co wins second US Fosamax trial on jaw damage claims
This article was originally published in Scrip
Executive Summary
Merck & Co has won the second federal bellwether case to go to trial in the US over claims that the company did not adequately warn about a link between its oral bisphosphonate Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). The jury unanimously found in the company's favour.